Publications scientifiques en oncologie

Sudocetaxel zendusortide (TH1902), a novel sortilin-receptor (SORT1)-targeting peptide-drug-conjugate (PDC) in patients (pts) with advanced solid tumors: Results from part 1 (dose-escalation) of a phase 1, open-label study
2023
Funda Meric-Bernstam, Satish Shah, Manish Sharma, Annick Metcalfe, Guylaine Roy, Lynn Marie Douglas, Christian Marsolais, Ira Seth Winer
The peptide-drug conjugate sudocetaxel zendusortide (TH1902) potentiates anti-tumoral activity of the anti-PD-L1 checkpoint inhibitor and induces immune cell infiltration in a B16-F10 syngeneic melanoma model
2023
Michel Demeule, Jean-Christophe Currie, Cyndia Charfi, Alain Zgheib, Isabelle Cousineau, Richard Béliveau, Christian Marsolais, Borhane Annabi
Differential expression of a novel transport receptor, SORT1 (sortilin), in cancer versus healthy tissues that can be utilized for targeted delivery of anti-cancer drugs
2023
Guylaine Roy, Pratik Kadekar, Lynn Marie Douglas, Maude Frappier, Jean-Christophe Currie, Jess Dhillon, Gregory Cesarone, Richard Siderits, Karen Kirchner, Michel Demeule, Christian Marsolais
Sudocetaxel zendusortide (TH1902), a peptide-drug conjugate for the treatment of sortilin-positive (SORT1+) TNBC and Her2-positive breast cancers
2023
Cyndia Charfi, Michel Demeule, Jean-Christophe Currie, Alain Zgheib, Bogdan Alexandru Danalache, Richard Béliveau, Christian Marsolais, Borhane Annabi
Expression of the sortilin receptor (SORT1) in healthy and tumor tissues
2022
Guylaine Roy, Pratik Kadekar, Lynn Marie Douglas, Jean-Christophe Currie, Jess Dhillon, Gregory Cesarone, Richard Siderits, Karen Kirchner, Michel Demeule, et Christian Marsolais